Nevro Corp. (NYSE:NVRO) Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $93.50, for a total transaction of $467,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael F. Demane also recently made the following trade(s):

  • On Wednesday, September 27th, Michael F. Demane sold 5,000 shares of Nevro Corp. stock. The shares were sold at an average price of $91.50, for a total transaction of $457,500.00.
  • On Wednesday, September 13th, Michael F. Demane sold 5,000 shares of Nevro Corp. stock. The shares were sold at an average price of $89.50, for a total transaction of $447,500.00.
  • On Monday, September 11th, Michael F. Demane sold 25,000 shares of Nevro Corp. stock. The shares were sold at an average price of $87.73, for a total transaction of $2,193,250.00.

Shares of Nevro Corp. (NVRO) opened at 92.82 on Thursday. The stock’s 50 day moving average is $88.61 and its 200 day moving average is $83.78. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $102.26. The stock’s market cap is $2.73 billion.

Nevro Corp. (NYSE:NVRO) last posted its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.11). The company had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The business’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.31) EPS. On average, equities analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Michael F. Demane Sells 5,000 Shares of Nevro Corp. (NVRO) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/michael-f-demane-sells-5000-shares-of-nevro-corp-nvro-stock/1624938.html.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Nevro Corp. by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,973,146 shares of the medical equipment provider’s stock valued at $146,862,000 after acquiring an additional 38,553 shares during the period. BlackRock Inc. raised its stake in shares of Nevro Corp. by 13.5% in the 2nd quarter. BlackRock Inc. now owns 1,787,896 shares of the medical equipment provider’s stock valued at $133,073,000 after acquiring an additional 212,656 shares during the period. Franklin Resources Inc. raised its stake in shares of Nevro Corp. by 8.8% in the 2nd quarter. Franklin Resources Inc. now owns 1,541,934 shares of the medical equipment provider’s stock valued at $114,748,000 after acquiring an additional 125,135 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Nevro Corp. by 5.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,486,197 shares of the medical equipment provider’s stock valued at $139,257,000 after acquiring an additional 73,615 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of Nevro Corp. in the 2nd quarter valued at $105,837,000.

NVRO has been the topic of a number of research reports. Zacks Investment Research raised shares of Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price target on the stock in a research note on Wednesday, August 2nd. Northland Securities set a $96.00 target price on shares of Nevro Corp. and gave the stock a “buy” rating in a research note on Thursday, June 15th. Canaccord Genuity reissued a “buy” rating and issued a $120.00 target price on shares of Nevro Corp. in a research note on Wednesday, July 5th. BMO Capital Markets reissued a “buy” rating and issued a $106.00 target price on shares of Nevro Corp. in a research note on Friday, September 1st. Finally, BidaskClub raised shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research note on Sunday, July 16th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $101.25.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.